How and where to order Bimatoprost (Latisse, Lumigan, Careprost) ophthalmic solution 0.03% 3 ml online:
LATISSE (BIMATOPROST) OPHTHALMIC SOLUTION 0.03%: PRESCRIBING INFORMATION (see "References")
DESCRIPTION
Latisse (Bimatoprost ophthalmic solution) 0.03% is a synthetic prostaglandin analog. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-5-Nethylheptenamide, and its molecular weight is 415.58. Its molecular formula is C25H37NO4.
Bimatoprost is a powder, which is very soluble in ethyl alcohol and methyl alcohol and slightly soluble in water. Latisse is a clear, isotonic, colorless, sterile ophthalmic solution with an osmolality of approximately 290 mOsmol/kg.
Active ingredients: Bimatoprost 0.3 mg/mL (0.03%)
Preservative: Benzalkonium Chloride 0.05 mg/mL
Inactive ingredients: sodium phosphate dibasic; sodium chloride; citric acid; purified water. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH. The pH during its shelf life ranges from 6.8 - 7.8.
DOSAGE AND ADMINISTRATION
Latisse dosage and administration
INDICATIONS AND USAGE
Latisse (Bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.
CONTRAINDICATIONS
Hypersensitivity
Latisse (Bimatoprost ophthalmic solution) is contraindicated in patients with hypersensitivity to bimatoprost or any other ingredient in this product.
WARNINGS
Latisse warnings
PRECAUTIONS
Latisse precautions
ADVERSE REACTIONS
Latisse adverse reactions
USE IN SPECIFIC POPULATIONS
Latisse use in specific populations
CLINICAL PHARMACOLOGY
Latisse clinical pharmacology
NONCLINICAL TOXICOLOGY
Carcinogenesis, Mutagenesis, Impairment of Fertility
Latisse (Bimatoprost) ophthalmic solution was not carcinogenic in either mice or rats when administered by oral gavage at doses of up to 2 mg/kg/day and 1 mg/kg/day respectively (approximately 192 and 291 times the recommended human exposure based on blood AUC levels after topical corneal and/or conjunctival sac administration respectively) for 104 weeks.
Bimatoprost was not mutagenic or clastogenic in the Ames test, in the mouse lymphoma test, or in the in vivo mouse micronucleus tests.
Latisse (Bimatoprost) eye drops did not impair fertility in male or female rats up to doses of 0.6 mg/kg/day.
CLINICAL STUDIES
Latisse clinical studies
HOW SUPPLIED / STORAGE AND HANDLING
Latisse (Bimatoprost ophthalmic solution) 0.03% is supplied sterile in opaque white low density polyethylene dispenser bottles and tips with turquoise polystyrene caps accompanied by 60 sterile, disposable applicators:
3 ml of solution in a 5 ml bottle.
Storage
Latisse should be stored at 2° to 25°C (36° to 77°F).
Manufactured and distributed by Allergan pharmaceutical company and its divisions.
|